How to Read Biotech Clinical Trial Data: Phase 1, 2, 3 Results Explained for Investors

If you are investing in biotech, you will eventually have to read clinical trial data. There is no way around it. Press releases can be misleading, analyst reports can be wrong, and Twitter is full of people who have never read a trial protocol in their life. The only way to really understand what is happening with a drug is to go to the data yourself.

The problem is that clinical trial results can feel impenetrable if you do not know what you are looking at. Words like "primary endpoint," "p-value," "overall survival," and "hazard ratio" get thrown around constantly, and if you do not understand them, you are making investment decisions based on other people's interpretations instead of your own.

This guide breaks all of it down. We will walk through what happens in each phase of a clinical trial, what the key endpoints mean, how to tell if results are actually good or just good enough for a press release, and what red flags to watch for. By the end, you will be able to read a Phase 3 data readout and form your own opinion on whether the data supports an FDA approval.

This is Part 2 of the BiopharmaWatch Biotech Investing Masterclass. If you have not read Part 1 yet, start with our beginner's guide to biotech investing.

Why Clinical Trial Data Is the Most Important Thing in Biotech

In biotech, the clinical data is everything. It is the evidence that tells the FDA whether a drug works, the proof that tells doctors whether to prescribe it, and the signal that tells investors whether the stock is worth holding.

Here is the reality: most drugs fail. About 90% of drugs that enter Phase 1 clinical trials never make it to market. The ones that succeed do so because the clinical data is strong enough to convince regulators, physicians, and payers that the drug is safe, effective, and better than what is already available.

As an investor, your job is to evaluate that data before the market fully prices it in. If you can read a Phase 2 readout and understand that the data is stronger than the market expects, you have an edge. If you can spot weaknesses in a Phase 3 press release that the headline writers missed, you can avoid a trap.

The BiopharmaWatch FDA Calendar tracks every upcoming data readout across biotech, so you always know when results are coming and can prepare to analyze them.

Phase 1 Trials: What Investors Need to Know

Phase 1 is where it all starts. This is the first time a drug is tested in humans, and the primary goal is safety, not efficacy.

What to look for in Phase 1 data

• Dose-limiting toxicities (DLTs). These are side effects so severe that the dose cannot be increased further. A clean Phase 1 with no DLTs at therapeutic doses is a good sign.
• Maximum tolerated dose (MTD). This is the highest dose patients can take without unacceptable side effects. You want to see that the MTD is well above the dose expected to be effective.
• Pharmacokinetics (PK). This describes how the body absorbs, distributes, metabolizes, and excretes the drug. Good PK data means the drug reaches the target tissue at the right concentration for the right amount of time.
• Early efficacy signals. Phase 1 trials are not designed to prove efficacy, but sometimes you see hints. Tumor shrinkage in an oncology Phase 1, for example, can generate significant investor excitement even though the trial was not powered to measure it.

Investor perspective on Phase 1

Phase 1 data rarely moves stocks dramatically unless there is a surprising safety issue or an unexpectedly strong efficacy signal. The real value of Phase 1 for investors is de-risking. A drug that passes Phase 1 safely has proven it can be given to humans, which is a meaningful step forward from preclinical data. But the stock has not priced in much yet, so the real value creation starts in Phase 2.

Phase 2 Trials: The Make-or-Break Moment

Phase 2 is where most biotech investors focus their attention, and for good reason. This is the first time you see real evidence of whether the drug actually works against the disease. It is also where the majority of drugs fail.

What to look for in Phase 2 data

• Did it hit the primary endpoint? This is the most important question. The primary endpoint is the main measure of success that the trial was designed to test. If the drug missed its primary endpoint, the trial failed, full stop.
• Statistical significance (p-value). You need a p-value below 0.05, which means there is less than a 5% chance the results happened by random chance. We will dive deeper into p-values later in this guide.
• Effect size. A statistically significant result is not always clinically meaningful. A blood pressure drug that lowers systolic pressure by 2 mmHg might achieve a p-value below 0.05, but no doctor is going to prescribe it. You need the effect to be large enough to matter.
• Dose response. Ideally, you want to see that higher doses produce better results, up to a point. A clear dose-response curve strengthens the case that the drug is actually causing the observed effect, not random noise.
• Safety profile. Side effects become more relevant in Phase 2 because you are now treating sick patients. The key is whether the benefit outweighs the risk. A cancer drug with significant side effects might still be acceptable because the alternative is death. A drug for mild eczema with the same side effects would never get approved.

Why Phase 2 is the biggest value inflection point

Phase 2 is where the risk-reward balance is most favorable for investors. Here is why:

• Before Phase 2 data, the market is pricing the drug at maybe 20% to 30% probability of success.
• Positive Phase 2 data can immediately re-rate that probability to 50% to 70%, which translates into a massive stock price increase.
• Conversely, negative Phase 2 data usually takes the probability close to zero, cratering the stock.

This is why professional biotech investors spend so much time analyzing Phase 2 trial designs before results come out. If you understand the trial well enough, you can sometimes estimate the probability of a positive readout and position accordingly.

Phase 3 Trials: The Final Test Before FDA

Phase 3 is the last and largest stage of clinical testing before a company can file for FDA approval. These trials are designed to definitively confirm that the drug works and that it is safe enough for widespread use.

What to look for in Phase 3 data

• Primary endpoint hit with strong statistical significance. A p-value well below 0.05 (like p less than 0.001) in Phase 3 is much more convincing than a borderline result. The FDA wants to see clear evidence.
• Consistency with Phase 2. If Phase 2 showed a 50% response rate and Phase 3 shows 30%, that is a red flag. Results should be in the same ballpark, even if they are slightly lower (which is normal because Phase 3 populations are larger and more diverse).
• Secondary endpoints. While the primary endpoint is what matters most for approval, strong secondary endpoints strengthen the overall story. They show that the drug is working through multiple measures, not just one.
• Subgroup analyses. The FDA will look at how the drug performs in different patient subgroups (age, gender, race, disease severity). If the drug works in some subgroups but not others, it could limit the label.
• Safety and tolerability in a large population. Phase 3 trials enroll thousands of patients, which means you are more likely to see rare side effects that were not apparent in smaller trials. New safety signals in Phase 3 can derail an otherwise strong efficacy readout.

The Phase 3 vs. Phase 2 gap

One of the most important things to understand as a biotech investor is that Phase 3 results are almost always slightly weaker than Phase 2 results. This is normal. Phase 2 trials typically enroll a more carefully selected patient population and are conducted at fewer sites with more oversight. Phase 3 trials are bigger, messier, and more reflective of the real world.

A drug that showed a 60% response rate in Phase 2 might show 45% to 50% in Phase 3. That does not mean the drug failed. It means the real-world effect is slightly lower than the ideal-conditions effect. As long as the drug still hits its primary endpoint with statistical significance, the Phase 3 is a success.

Understanding Endpoints: OS, PFS, ORR and What They Mean

Endpoints are the specific measurements used to determine whether a drug works. Different diseases use different endpoints, and understanding them is critical for reading trial results. Here are the most important ones:

Primary vs. secondary endpoints

Every clinical trial has a primary endpoint, which is the main outcome the trial is designed to measure. This is what the FDA cares about most. If the drug hits the primary endpoint with statistical significance, the trial is considered a success.

Secondary endpoints are additional measures that provide supporting evidence. For example, a cancer trial might have overall survival as the primary endpoint and progression-free survival, overall response rate, and quality of life as secondary endpoints. Strong secondary endpoints make the overall data package more compelling, but they cannot save a trial that missed its primary endpoint.

Statistical Significance: What P-Values Actually Tell You

You will see p-values in every clinical trial readout, so you need to understand what they mean and, just as importantly, what they do not mean.

What is a p-value?

A p-value tells you the probability that the results you observed could have happened by random chance if the drug had no effect at all. A p-value of 0.05 means there is a 5% chance the results are due to chance. A p-value of 0.001 means there is a 0.1% chance.

The standard threshold for "statistical significance" in clinical trials is p less than 0.05. If the p-value is below 0.05, the result is considered statistically significant. If it is above 0.05, the trial technically failed to demonstrate a statistically significant effect.

What p-values do NOT tell you

• A p-value does not tell you how big the effect is. A drug could lower blood pressure by 1 mmHg with a p-value of 0.001 (because the trial was enormous). That is statistically significant but clinically meaningless.
• A p-value does not tell you the drug works in every patient. It tells you the average effect across the trial population. Some patients might benefit enormously. Others might not respond at all.
• A p-value of 0.06 does not mean the drug failed. It means the trial did not reach the pre-specified threshold. Sometimes a trial is just slightly underpowered. The FDA looks at the totality of the data, not just one number.

Other statistics to watch

Red Flags in Clinical Trial Results

Not all positive-sounding data is actually positive. Here are the red flags to watch for when you read a clinical trial press release or data presentation:

• The press release emphasizes secondary endpoints over the primary endpoint. If a company leads with "positive trends" in secondary measures and buries the primary endpoint result, it usually means the primary endpoint was missed or barely met.
• P-value is "one-sided" or uses a non-standard threshold. The standard is a two-sided p-value less than 0.05. If the company reports a one-sided p-value, the actual two-sided p-value is roughly double that. This is sometimes used to make results look better than they are.
• Post-hoc subgroup analyses that were not pre-specified. If a company reports that the drug worked in patients over 65 but not in the overall population, and that subgroup analysis was not planned before the trial started, treat it with extreme skepticism. You can always find a subgroup that looks good if you slice the data enough ways.
• High dropout rates. If a significant percentage of patients dropped out of the trial, it raises questions about tolerability and can bias the results. Patients who drop out are often the ones having the worst outcomes.
• The control group performed unusually well or poorly. Sometimes a drug looks effective not because it worked well, but because the control group did worse than expected. Check whether the control group outcomes are consistent with historical data for that disease.
• No dose-response relationship. If the low dose and high dose produce similar results, it raises questions about whether the drug is actually driving the outcome or if something else is going on.
• "Clinically meaningful" without statistical significance. If a company claims results are "clinically meaningful" but does not report statistical significance, the results probably were not statistically significant. Clinically meaningful and statistically significant are two different things, and you need both.

How to Use BiopharmaWatch to Track Trial Readouts

Staying on top of clinical trial data readouts is one of the most important things you can do as a biotech investor. Here is how to use the tools available on BiopharmaWatch:

• FDA Calendar tracks every upcoming data readout, PDUFA date, and advisory committee meeting. You can filter by stage (Phase 1, 2, 3), therapeutic area, or search by ticker. Each catalyst includes a Probability of Approval (POA) score to help you assess risk.
• Hedge Fund Tracker shows how institutional investors are positioning before major catalysts. If major biotech hedge funds are building positions ahead of a data readout, it is worth paying attention.

Before any data readout, do your homework. Read the trial protocol on ClinicalTrials.gov. Understand the primary endpoint, the patient population, the comparator, and the expected timeline. That way, when the data drops, you can analyze it yourself instead of relying on headlines.

Frequently Asked Questions

What is a clinical trial endpoint?

A clinical trial endpoint is the specific measurement used to determine whether a drug works. The primary endpoint is the main outcome the trial is designed to test, like overall survival in a cancer trial or HbA1c reduction in a diabetes trial. Secondary endpoints provide additional supporting evidence.

What does p-value mean in clinical trials?

A p-value is the probability that the observed results could have happened by random chance if the drug had no effect. The standard threshold for statistical significance is p less than 0.05, meaning there is less than a 5% chance the results are due to chance. Lower p-values (like p less than 0.001) indicate stronger evidence.

What is the difference between Phase 2 and Phase 3 clinical trials?

Phase 2 trials test whether a drug works in 100 to 300 patients and determine the optimal dose. Phase 3 trials confirm those results in a much larger population of 1,000 to 3,000 or more patients. Phase 3 trials are the final step before a company can file for FDA approval. Phase 2 has a success rate of about 33%, while Phase 3 has a success rate of about 50% to 60%.

What is Overall Survival vs. Progression-Free Survival?

Overall Survival (OS) measures how long patients live from the start of treatment. It is the gold standard endpoint in oncology. Progression-Free Survival (PFS) measures how long patients live without their disease getting worse. PFS is faster to measure, which is why it is often used for accelerated approvals, but it does not always translate into patients actually living longer.

What is a hazard ratio?

A hazard ratio compares the risk of an event (like death or disease progression) between the treatment group and the control group. A hazard ratio of 0.7 means patients on the drug have a 30% lower risk of the event compared to the control group. A hazard ratio below 1.0 favors the treatment, and lower values indicate a stronger treatment effect.

How do I know if clinical trial results are actually good?

Good clinical trial results have four characteristics: the primary endpoint was hit with strong statistical significance (p less than 0.05, ideally much lower), the effect size is clinically meaningful (not just statistically significant), the safety profile is acceptable relative to the benefit, and the results are consistent with earlier-phase data. If any of these are missing, dig deeper before getting excited.

What happens after a successful Phase 3 trial?

After a successful Phase 3, the company compiles all the data into a New Drug Application (NDA) or Biologics License Application (BLA) and submits it to the FDA. The FDA then has 60 days to decide whether to accept the filing for review, and if accepted, sets a PDUFA date, which is the target decision date. The review typically takes 6 to 10 months. You can track all upcoming PDUFA dates on the BiopharmaWatch FDA Calendar.

Why do Phase 3 results sometimes look worse than Phase 2?

This is normal and expected. Phase 2 trials enroll a more carefully selected patient population and are typically conducted at fewer sites with more controlled conditions. Phase 3 trials are larger, enrolling thousands of patients across many sites worldwide, which introduces more variability. An effect size that drops 10% to 20% from Phase 2 to Phase 3 is common and does not necessarily indicate a problem, as long as the primary endpoint is still met with statistical significance.

What Comes Next

Now that you know how to read clinical trial data, the next step is putting it all together into a complete due diligence framework. In Part 3 of this series, we cover the full biotech due diligence checklist, including how to evaluate a drug pipeline, assess probability of approval scores, analyze the balance sheet, and read the hedge fund and insider signals that can give you an edge.

In the meantime, explore the BiopharmaWatch FDA Calendar to see which data readouts are coming up this quarter and start practicing your analysis.

This article is for educational purposes only and does not constitute financial or investment advice. Biotech investing carries significant risk. Always do your own research and consider consulting a financial advisor before making investment decisions.